1Sever P.New hypertension guidelines from the National Institute forHealth and Clinical Excellence and the British Hypertension society[J].J Renin Angiotensin Aldosterone Syst,2006;7(2):61-3.
2Mancia G,de Backer G,Dominiczak A,et al.2007 Guideline for manage-ment of arterial hypertension:the task force for the management of arterialhypertension of the European Society of Hypertension and of the EuropeanSociety of Cardiology[J].J Hypertens,2007;25(6):1105-88.
4Suzuki H,Moriwaki K,Kanno Y,et al.Comparison of the effects of anACE inhibitor and alphabeta blocker on the progression of renal failurewith left ventricular hypertrophy:preliminary report[J].Hypertens Res,2001;24(1):153-8.
5Suzuki H,Nakamoto H,Nemoto H,et al.Control of blood pressure andprevention of end-organ damage in patients with accelerated hypetensionby combination with arotinolol and extended release nifedipine[J].Hy-pertens Res,2000;23(1):159-66.
5MONTASTRUC JL, PATHAK A, LAPEYRE-MESTRE M. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study[J]. Lancet, 2002, 359(9324) :2202,
6PEPINE CJ, HARDBERG EM, COOPERoDEHOFF RM, et al. A calcium vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease[J]. JAMA, 2003, 290(21 ) : 2805-2816.
7MERCURI M, TANG R, PHILLIPS RM, et al. Ultrasound protocol and quality control procedures in the European Lacidipine Study on Atherosclerosis (ELSA) [J].Blood Press Suppl, 1996, 4 : 20-23.
8DAHLOF B, SEVER PS, POULTER NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding pefindopfil as required versus atenolol adding as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT- BPLA): a muhicentre randomised controlled trial[J]. Lancet, 2005, 366(9489): 895-906.
9UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39[J]. BMJ, 1998, 317(7160) : 713-720.
10SUNDSTROM J, RISERUS U, BYBERG L Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study[J]. BMJ, 2006, 332(7546): 878-882.
4Weissheimer KV, Franci CR, Lucion AB, et al. The role of AT 1 recep- tor-mediated reproductive function in renovascular hypetension in male rats[ J]. Horm Behav,2012,62( 1 ) :43-49.
5Yerram P, Karuparthi PR, Chaudhary K. Pathogenesisis and management of renovascular hypertension and ischemic nephropathy[J] . Minerv Uorl Nofrol,2012,64( 1 ) :63.
